{
    "body": "What is the indication of ARCALYST?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22096352", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19707454", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19649332"
    ], 
    "ideal_answer": [
        "In February 2008, Regeneron received Orphan Drug approval from the Food and Drug Administration for rilonacept in the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, namely, familial cold-induced autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for children and adults 12 years and older."
    ], 
    "exact_answer": [
        "cryopyrin-associated periodic syndromes (CAPS) disorders"
    ], 
    "type": "factoid", 
    "id": "58df47f08acda3452900002f", 
    "snippets": [
        {
            "offsetInBeginSection": 526, 
            "offsetInEndSection": 775, 
            "text": "Rilonacept (Arcalyst(TM); Regeneron) is the first us Food and Drug Administration-approved treatment for familial cold autoinflammatory syndrome and Muckle-Wells syndrome and the first in a new line of drugs designed for longer-acting IL-1 blockade.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22096352", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 401, 
            "offsetInEndSection": 735, 
            "text": " In February 2008, Regeneron received Orphan Drug approval from the Food and Drug Administration for rilonacept in the treatment of two cryopyrin-associated periodic syndromes (CAPS) disorders, namely, familial cold-induced autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), for children and adults 12 years and older. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649332", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1271, 
            "offsetInEndSection": 1605, 
            "text": "In February, 2008, 'Orphan Drug' approval from the Food and Drug Administration (FDA) for rilonacept (IL-1 Trap/Arcalyst(), Regeneron Pharmaceuticals, Inc) was given for the treatment of two CAPS disorders, FCAS and MWS in adults and children 12 years and older, making rilonacept the first therapy approved for the treatment of CAPS.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19707454", 
            "endSection": "abstract"
        }
    ]
}